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that approximately 17% of the US adult population has 
CKD  [1, 2] . While the growing burden of diabetes and 
hypertension, in conjunction with the general ageing of 
the population, has contributed to the increased preva-
lence of CKD, the obesity epidemic has also played a sig-
nificant role  [3] .
 Over the last three decades, obesity prevalence has 
more than doubled among US adults. In the most recent 
National Health and Nutrition Examination Survey 
(NHANES), 32.2% of US adults met the clinical criteria 
for obesity with a body mass index (BMI) of  6 30  [4] . The 
rising prevalence of obesity has been matched by a paral-
lel increase in the prevalence of metabolic syndrome. 
This clinical syndrome, marked by abdominal obesity, 
hypertriglyceridemia, low HDL cholesterol, elevated 
blood pressure, and impaired insulin sensitivity, is de-
tectable in roughly 1 in 3 US adults  [5] . Therefore, any 
discussion of the renal effects of obesity and metabolic 
syndrome must begin with diabetes and hypertension, 
which together account for roughly 70% of CKD  [1, 2] .
 The vast majority of hypertensive and diabetic pa-
tients are either overweight or obese, and rising BMI is 
inversely related to control of disease. Among diabetic 
patients, for example, obesity is associated with poorer 
control of blood glucose, blood pressure, and cholesterol, 
heightening the risk for macrovascular (i.e. cardiac) and 
microvascular (i.e. renal) complications  [6] . In fact, much 
of the attention paid to obesity as a risk factor for kidney 
disease has aptly focused on its links to diabetes and hy-
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 Abstract 
 Obesity and obesity-associated kidney injuries have played 
an important role in the rising prevalence of chronic kidney 
disease (CKD). The link between obesity and kidney disease 
begins with obesity’s well-known associations with diabetes 
and hypertension, the two leading etiologies of CKD. How-
ever, a growing body of evidence suggests that elevated 
 aldosterone levels and expanded extracellular volume are 
key components of obesity-induced renal disease via aldo-
sterone’s non-epithelial effects on the kidney. Highlighting 
these blood pressure- and diabetes-independent mecha-
nisms of kidney injury in obesity allows an exploration of 
whether mineralocorticoid receptor blockade, coupled with 
weight loss and salt restriction, is an optimal treatment for 
overweight CKD patients. 
 
Copyright © 2009 S. Karger AG, Basel 
 Introduction 
 Chronic kidney disease (CKD) is associated with pre-
mature mortality, decreased quality of life, and increased 
healthcare expenditures. The prevalence of CKD has ris-
en at an alarming rate, with recent estimates suggesting 
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pertension. Nevertheless, a growing body of evidence has 
emerged suggesting that obesity by itself – independent 
of its association with hypertension and/or diabetes – is 
a key player in renal injuries  [7–12] . In this narrative re-
view, we examine the evidence that the interaction of al-
dosterone and extracellular volume is a crucial compo-
nent of obesity-associated kidney disease.
 Obesity-Induced Kidney Injury Independent of 
Hypertension and Diabetes 
 A number of recent clinical and epidemiological stud-
ies suggest that obesity itself – independent of its ties to 
diabetic and hypertensive disease risk – can play an im-
portant role in the development of CKD. A multivariate, 
cross-sectional analysis of NHANES data found a graded 
association between higher BMI and reduced kidney 
function (measured by serum cystatin C), with odds ratios 
(95% CI) of elevated serum cystatin C of 1.46 (1.02–2.10) 
for overweight (BMI 25.0–29.9), 2.36 (1.56–3.57) for class 
I obesity (BMI 30.0–34.9), and 2.82 (1.56–5.11) for class 
II–III obesity (BMI  6 35.0)  [13] . Pooled data from the Ath-
erosclerosis Risk in Communities Study (ARIC) and Car-
diovascular Health Study (CHS) demonstrated that waist-
to-hip ratio (WHR), a preferred anthropomorphic mea-
sure of obesity, was a better predictor than BMI of incident 
CKD  [14] . A Turkish study of 110 otherwise healthy obese 
patients (i.e. non-diabetic, non-hypertensive) showed a 
significant and independent association between BMI 
and CKD that may be due to occult inflammation given 
the correlation between elevated BMI and C-reactive pro-
tein levels in this study  [15] . And a prospective cohort of 
8,792 healthy Korean men without known risk factors for 
CKD found that increases in body weight, even when the 
BMI remained within normal range, were independently 
associated with increased risk for CKD  [16] .
 The recent study by Serra et al.  [17] deserves special 
mention for the novelty of its methods in examining the 
obesity-CKD relationship. These investigators performed 
kidney biopsies on 95 extremely obese (i.e. BMI  6 40) pa-
tients without clinical signs of renal dysfunction who 
were undergoing bariatric surgery. Only about half of 
these patients were hypertensive, and less than 15% were 
diabetic. The renal biopsies revealed a variety of glomer-
ular lesions, including increased mesangial matrix, me-
sangial cell proliferation, podocyte hypertrophy, and glo-
merulomegaly. The investigators propose that the early 
lesions found in this study are potential harbingers of fu-
ture overt kidney disease.
 A number of mechanisms have been proposed as ex-
planations for the obesity-CKD relationship, including 
chronic inflammation, abnormal vascular remodeling, 
and renal lipotoxicity  [7] . These routes of injury can oc-
cur in the absence of diabetes and hypertension, although 
the comorbidities likely exacerbate the damage. Perhaps 
the best described mechanism of obesity-induced kidney 
injury involves the adverse effects of increased body mass 
and subsequent increased glomerular filtration rate 
(GFR) per intact nephron. A hyperfiltration injury en-
sues, as obesity induces, even at ‘normal nephron capac-
ity’, the adaptations characteristic of reduced nephron 
number in CKD  [18] . Another proposed mechanism in-
volves adiponectin, a hormone produced by adipocytes 
that regulates glucose and lipid metabolism. This adipo-
cytokine is decreased in obesity, with levels of adiponec-
tin shown to be inversely related to the degree of albu-
minuria in obese patients  [19, 20] . Adiponectin knockout 
mice have profound proteinuria and, on histology, foot 
process effacement that both improve with exogenous 
adiponectin treatments  [21] . The end result of these kid-
ney injury pathways can be a proteinuric kidney disease 
termed obesity-associated glomerulopathy, which on his-
tology ranges from glomerulomegaly alone to a second-
ary focal segmental glomerulosclerosis pattern  [22] .
 Non-Epithelial Effects of Aldosterone 
 Over the last decade, aldosterone has emerged as a key 
agent in the pathophysiology of progressive kidney dis-
ease  [23, 24] . In addition to its classic, epithelial effects of 
promoting sodium retention (and potassium and magne-
sium excretion), aldosterone activates mineralocorticoid 
receptors in non-epithelial tissues of the heart, periph-
eral vasculature, and kidney to foster inflammation and 
fibrosis. These non-epithelial, injurious effects of aldo-
sterone occur in the presence of normal to high sodium 
cofactor, defined as high sodium intake with expanded 
extracellular volume  [25] . The harmful interaction be-
tween aldosterone and expanded extracellular volume 
may be a key component of the pathogenesis of obesity-
induced kidney injury.
 In animal models, unopposed aldosterone in the pres-
ence of high salt intake causes proteinuria via thrombot-
ic and proliferative lesions in the glomeruli and renal ves-
sels  [26–29] . These pathologic lesions occur independent 
of blood pressure, reflecting a direct, non-epithelial, pro-
inflammatory, profibrotic effect of aldosterone on the 
kidney. Observational human studies have also high-
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lighted the interplay between aldosterone and extracel-
lular volume in renal injuries. In the Primary Aldoste-
ronism Prevalence in Italy (PAPY) study, for example, 
despite essentially equal blood pressures and sodium in-
takes, subjects with primary aldosteronism had signifi-
cantly higher albuminuria rates than essential hyperten-
sive subjects with low to normal aldosterone levels  [30] . 
In other studies among resistant hypertensive subjects, 
higher aldosterone levels were correlated with higher de-
grees of proteinuria; moreover, among the high aldoste-
rone subjects, the elevations in proteinuria were linearly 
related to 24-hour urinary sodium levels (a surrogate for 
extracellular volume)  [31, 32] . Thus, while hyperaldoste-
ronism and expanded extracellular volume can, individ-
ually, be risk factors for kidney injury, their combined 
presence likely exhibits a multiplicative effect  [33] . This 
pathological milieu likely exists in obesity.
 Hyperaldosteronism of Obesity 
 Obesity and the metabolic syndrome are frequently 
associated with elevated levels of aldosterone  [34–39] , 
and intentional weight loss typically reduces aldosterone 
levels  [40, 41] . Adipocytes express a renin-angiotensin 
system and are consequently able to produce angiotensin 
II, traditionally the key stimulator of adrenal production 
of aldosterone  [42, 43] . This fat-based renin-angiotensin 
system, however, is likely only one component of aldoste-
rone overproduction in obesity. Excess adipose tissue ap-
pears to provide a medium in which aldosterone secre-
tion is further stimulated by angiotensin II-independent 
routes.
 Obesity is characterized by increased plasma fatty ac-
ids and oxidative stress; the most readily oxidized fatty 
acids are the polyunsaturated acids, the most abundant 
of which is linoleic acid. Goodfriend et al.  [44] tested the 
effects of oxidized derivatives of linoleic acid on rat adre-
nal cells. One derivative, 12,13-epoxy-9-keto-10 (trans) -
octadecenoic acid, was particularly potent, stimulat-
ing aldosteronogenesis    at   concentrations   from   0.5   to  
5   mol/l. This experiment suggests that, in the obese 
state, oxidized fatty acids likely stimulate aldosterono-
genesis independent of physiological control by angioten-
sin II and volume status.
 Ehrhart-Bornstein et al.  [45] created a fat cell-condi-
tioned medium to test the hypothesis that adipocyte se-
cretory products directly stimulate adrenocortical aldo-
sterone secretion. In vitro, human adrenocortical cells 
were placed in this fat cell-conditioned medium and, in a 
24-hour incubation period, increased aldosterone secre-
tion 7-fold. Concomitant incubation with the angioten-
sin receptor blocker, valsartan, did not significantly re-
duce this aldosterone secretion, confirming that the 
 aldosterone-stimulating effect was not angiotensin II-
mediated. At least two mineralocorticoid-releasing fac-
tors – an active (MW  1 50 kDa) and an inactive (MW  ! 50 
kDa) fraction – were identified by fractionation of the fat 
cell medium, but these investigators were not able to fur-
ther categorize these potent, adipocyte-secreted aldoste-
rone-stimulating factors  [45] .
 Complement-C1q TNF-related protein 1 (CTRP1), a 
member of the CTRP superfamily, may turn out to be one 
of these mineralocorticoid-releasing factors. In an exper-
iment with obese, diabetic rats, Jeon et al.  [46] recently 
investigated stimulation of aldosterone production by 
CTRP1, which is expressed at high levels in adipose tissue 
and in the zona glomerulosa of the adrenal cortex, the site 
of aldosterone production. In addition to finding a dose-
dependent increase in aldosterone production by CTRP1, 
they also found that angiotensin II-induced aldosterone 
production was, at least in part, mediated by the stimula-
tion of CTRP1 secretion  [46] .
 These pathophysiological links between visceral adi-
posity and aldosterone secretion suggest that obese pa-
tients may be constitutively stimulated to produce aldo-
sterone, and obesity can thus be viewed as a state of rela-
tive hyperaldosteronism. For example, in the study by 
Gaddam et al.  [32] of 279 resistant hypertensive patients, 
the  mean BMI was 33.0, the mean plasma aldosterone 
was 13.0 ng/dl, and the mean urine aldosterone was 13.0 
  g/24 h. Given that these obese subjects’ mean urinary 
sodium excretion was 187 mEq/24 h, these values suggest 
disordered aldosterone regulation, with the average pa-
tient in the study essentially meeting clinical criteria for 
primary aldosteronism (urine aldosterone  1 12.0   g/24 h 
with urine sodium  1 200 mEq/24 h)  [47] .
 Obesity and Expanded Extracellular Volume 
 Obesity and the metabolic syndrome are states of im-
paired sodium excretion  [48] . This natriuretic handicap 
is likely caused by insulin resistance and/or hyperglyce-
mia, as increased filtered glucose stimulates tubular re-
absorption of filtered sodium  [49] . An alternative theory 
is that the hyperfiltration of obesity causes a concomitant 
hyperactivity of the proximal tubule, with subsequent ex-
cessive sodium reabsorption  [50] . The impaired sodium 
excretion in obesity has been postulated as the root of 
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obesity-associated hypertension  [51, 52] . In this case, the 
combination of retained sodium and increased aldoste-
rone works via traditional epithelial routes to raise blood 
pressure and potentially damage the kidney.
 Yet potentially more harmful to the kidney are the 
non-epithelial effects of aldosterone and expanded extra-
cellular volume, the sequelae of sodium retention. Be-
cause obesity is characterized by both relative hyperaldo-
steronism and expanded volume, an obese individual is 
chronically subjected to higher degrees of the volume-al-
dosterone interaction than a non-obese individual ( fig. 1 ). 
In other words, the obese individual not only has a defec-
tive salt-excreting mechanism, but also has a relatively 
defective renin-angiotensin-aldosterone system, unable 
to suppress aldosterone levels in response to extracellular 
volume expansion as effectively as a non-obese individu-
al. The result of these parallel defects – a ‘double hit’ of 
expanded volume and relative hyperaldosteronism – can 
be fibrosis, inflammation, and, ultimately, end-organ 
damage in the kidney ( fig. 2 ).
 Speculatively, this ‘double hit’ theory of expanded vol-
ume and relative hyperaldosteronism may be particular-
ly important in African-Americans, an ethnic group with 
high prevalences of hypertension and obesity. Hyperten-
sion is typically more severe in African-Americans than 
in whites, with higher morbidity and mortality, including 
progression to end-stage kidney disease  [53, 54] . In a 
study of 234 African-Americans and 279 white French 
Canadians, African-Americans with and without hyper-











 Fig. 1. Proposed relationship between aldosterone and extracel-
lular volume in obese and non-obese individuals. These aldoste-
rone-volume curves are based on the aldosterone-sodium curves 
reported by Brunner et al.  [70] . The expansion of extracellular 
volume, which typically occurs via a salt load, should lead to sup-
pression of aldosterone levels as represented by the dashed line. 
Obese individuals (solid line), however, possess a natriuretic 
handicap and therefore are hypothesized to be subject to both 
higher states of extracellular volume and, for such states, rela-
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 Fig. 2. Obesity is characterized by elevated 
aldosterone and expanded extracellular 
volume. While oxidized fatty acids and ad-
ipokines stimulate aldosterone production 
from the adrenal gland, the hyperglycemia 
and insulin resistance of the metabolic 
syndrome impose a natriuretic handicap 
and subsequent volume expansion. This 
harmful interaction of inappropriately el-
evated aldosterone and expanded extra-
cellular volume is the ‘double hit’ of obe-
sity, leading to activation of non-epithelial 
mineralocorticoid receptors in the kid-
ney. The resulting inflammation and fi-
brosis can lead to end-organ damage with 
glomerulosclerosis and proteinuria. This 
route of kidney injury occurs independent 
of obesity’s well-known links to kidney 
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ence, and percent body fat than their French Canadian 
counterparts  [55] . Among the hypertensive subjects in 
this study, African-Americans also had lower plasma re-
nin activity (PRA, an inverse measurement of volume 
status), higher aldosterone levels, and higher aldoste-
rone/PRA ratios than whites: 26.2 versus 8.4 when su-
pine, 27.4 versus 8.0 when standing (p  ! 0.0001 for both 
comparisons). Another report from these same investiga-
tors, studying 397 African-Americans of whom roughly 
half were hypertensive, identified the metabolic syn-
drome in 17% of all subjects  [56] . The prevalence of hy-
pertension in metabolic syndrome subjects was 94% 
compared to 37% in subjects without metabolic syn-
drome, and metabolic syndrome subjects had signifi-
cantly higher aldosterone levels, lower PRA levels, and 
higher aldosterone/PRA ratios. This group recently pub-
lished data on 217 normotensive and 224 hypertensive 
African-Americans, in which hypertensive subjects, with 
mean BMI of 28.9  8 0.3 compared to 27.2  8 0.3 in nor-
motensives (p  ! 0.0001), again manifested markedly 
higher aldosterone and lower PRA levels than their lean-
er, normotensive counterparts  [57] . This ‘mild variant of 
primary aldosteronism’ (a phrase used by these authors) 
was associated with reduced vascular compliance and in-
creased renal vascular resistance. Overall, African-Amer-
icans with overweight and obesity appear to be at high 
risk for high aldosterone and low renin levels that suggest 
a hyperaldosterone and hypervolemic state. While ele-
vated blood pressures play a key role in the resultant hy-
pertensive end-organ damage, injuries to the heart and 
kidney may also be due, in part, to the blood-pressure 
independent, non-epithelial effects of aldosterone in this 
milieu of expanded volume and relative hyperaldoste-
ronism.
 Treating Obesity-Associated Kidney Disease 
 Fortunately, therapies exist that may prevent or at least 
attenuate some of the renal injuries of obesity by blocking 
aldosterone and/or reducing extracellular volume. Per-
haps the best therapy is simple weight loss which, as not-
ed above, leads to decreased aldosterone levels as well as 
improved glycemic and blood pressure control  [6, 40, 41] . 
A salt-restricted diet is another treatment option that can 
address volume expansion, as are diuretics. To date, there 
have been no prospective studies on the effects of bariat-
ric surgery on kidney function, but theoretically such an 
intervention should benefit the kidney from the stand-
point of both extracellular volume and aldosterone. Re-
cent retrospective analyses suggest that bariatric surgery 
leads to improvements in glomerular filtration rate and 
reductions in albuminuria in patients with preexisting 
kidney disease  [58, 59] . Aldosterone levels were not re-
ported in these patients, but the concomitant reductions 
in high-sensitivity C-reactive protein levels suggest that 
weight loss surgery reduced overall inflammation and 
that the renal benefits were not solely due to blood pres-
sure reduction  [60] .
 The role of aldosterone in obesity-related kidney in-
jury is crucial when considering pharmacological treat-
ment options. Angiotensin-converting enzyme (ACE) in-
hibitors have been shown to ameliorate podocyte damage 
in obese rats, perhaps through downstream suppression 
of aldosterone  [61] . Mineralocorticoid receptor blockers, 
such as spironolactone and eplerenone, which target both 
the epithelial and non-epithelial effects of aldosterone, 
have shown very promising results in animal studies of 
obesity-associated kidney disease. In dogs fed a high fat 
diet, simultaneous treatment with eplerenone (compared 
with untreated animals) markedly attenuated obesity-in-
duced glomerular hyperfiltration, sodium retention, and 
hypertension  [62] . Proteinuria in a rat model of metabol-
ic syndrome was correlated with aldosterone levels and 
accompanied histologically by podocyte injury that, 
along with proteinuria, markedly improved after admin-
istration of mineralocorticoid receptor blockade  [63–65] . 
Two small clinical studies, both currently in abstract 
form, have shown that mineralocorticoid receptor block-
ade significantly reduces urinary protein excretion  [66, 
67] . Notably, the mean pretreatment aldosterone levels of 
subjects in both studies were greater than mean popula-
tion aldosterone values  [68] , supporting the notion that 
obesity is a hyperaldosterone state and highlighting why 
direct aldosterone blockade may have been so effective in 
these patients.
 Ideally, all obese patients should try to lose weight – by 
diet, surgery, or both measures. However, given how dif-
ficult it can be to achieve and maintain substantial weight 
loss, we also suggest checking obese patients’ aldosterone 
levels, particularly if there is clinical evidence of renal 
dysfunction (which would include proteinuria and diffi-
cult to manage hypertension). If the aldosterone concen-
tration is normal to elevated, a mineralocorticoid recep-
tor blocker and salt restriction could be prescribed for 
renal protection. Alternatively, empiric treatment with 
mineralocorticoid receptor blockers and a low-salt diet 
may be undertaken even without aldosterone measure-
ments, recognizing the possibility that mineralocorticoid 
receptor activation may also occur via elevated cortisol 
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